{
    "clinical_study": {
        "@rank": "146241", 
        "acronym": "OUCH", 
        "arm_group": {
            "arm_group_label": "Anesthetic Topical Adhesive Synera", 
            "arm_group_type": "Other", 
            "description": "Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.\nFor subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if applying an anesthetic topical adhesive, Synera\u00ae,\n      will reduce the injection pain. Relieving injection site pain may improve the tolerability\n      of Multiple Sclerosis medications.\n\n      Study Hypothesis: Pre-medication with Synera will have a significant effect on pain ratings\n      as measured by the visual analog scale and Local injection site reaction scale."
        }, 
        "brief_title": "Pilot Study of Anesthetic Topical Adhesive (Synera\u2122) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Open-label prospective study of Synera to reduce injection pain in 30 patients with\n      relapsing forms of Multiple Sclerosis taking interferon beta or glatiramer acetate.  The\n      duration will be 3-6 weeks (1-2 weeks of baseline observation followed by 2-4 weeks of\n      on-drug observation), depending on which Multiple Sclerosis drug product is being studied.\n      The study will include down-titration from 60 to 30 minutes of application to assess for any\n      difference in responses.  We define one primary outcome measure,\"pain upon injection\" by\n      visual analog scale (VAS).  Secondary measures will include 24-hour ratings of pain by VAS\n      and 24-hour local injection site reaction (LISR) scale score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of Multiple Sclerosis based on McDonald or Poser criteria (no\n             sub-type restrictions)\n\n          -  Aged >18\n\n          -  Regular use of one of the follow Multiple Sclerosis medication treatments: interferon\n             beta subcutaneous (15 subjects, Betaseron, Extavia or Rebif), or glatiramer acetate\n             subcutaneous (15 subjects, Copaxone).\n\n          -  No change in disease modifying therapy in 60 days.\n\n          -  Mean score of  \u22651.0 on Local Injection Site Reaction scale and Mean Pain Upon\n             Injection score \u22654.0 during baseline period.\n\n          -  At least 4 valid diary entries over screening period.\n\n          -  No Multiple Sclerosis exacerbation for 60 days prior to screening.\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Females who are breast-feeding, pregnant or have potential to become pregnant during\n             the course of the study (fertile and unwilling/unable to use effective contraceptive\n             measures).\n\n          -  Cognitive deficits that would interfere with the subject's ability to give informed\n             consent or perform study testing.\n\n          -  Concurrent application of any topical medication to treat injection site reactions\n             from screening through final visit.\n\n          -  History of allergy to lidocaine, tetracaine or PABA (para-amino benzoic acid)\n             containing products.\n\n          -  Patients receiving class 1 antiarrhythmic agents (i.e. tocainide, mexiletine)\n\n          -  Any other serious and/or unstable medical condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834586", 
            "org_study_id": "TRB 2012"
        }, 
        "intervention": {
            "arm_group_label": "Anesthetic Topical Adhesive Synera", 
            "description": "For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.\nFor subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week", 
            "intervention_name": "Anesthetic Topical Adhesive Synera", 
            "intervention_type": "Drug", 
            "other_name": "Synera"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Anesthetics, Local", 
                "Copolymer 1"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 16, 2013", 
        "location": {
            "contact": {
                "email": "clgonzales@evergreenhealth.com", 
                "last_name": "Carey Gonzales, Research", 
                "phone": "425-899-5374"
            }, 
            "facility": {
                "address": {
                    "city": "Kirkland", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98034"
                }, 
                "name": "MS Center at Evergreen Health"
            }, 
            "investigator": [
                {
                    "last_name": "Theodore R Brown, MD, MPH", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Virginia Simnad, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of Anesthetic Topical Adhesive (Synera\u2122) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH)", 
        "overall_contact": {
            "email": "clgonzales@evergreenhealth.com", 
            "last_name": "Carey Gonzales, Research", 
            "phone": "425-899-5374"
        }, 
        "overall_official": {
            "affiliation": "Evergreen Health", 
            "last_name": "Theodore R Brown, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary Outcome Measure\n\u2022Change from baseline in rating of pain upon injection, recorded immediately post-injection on a 0-10 Visual Analog Scale (VAS)Pain upon injection, recorded immediately post-injection on a 0-10 Visual Analog scale (VAS)", 
            "measure": "Pain Rating", 
            "safety_issue": "No", 
            "time_frame": "at 60 and 30 minute applications"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834586"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pain after 12-hours, defined as the level of injection-site pain at the  12 hour mark on a 0-10 VAS.\nAverage Pain Rating over 24-hours, defined as the average injection-site pain over 24-hours on a 0-10 VAS.\nLISR scale score at 24-hours post-injection. (See Appendix 1)\nFear of injection, recorded immediately before injection on a 0-10 VAS\nSubject global impression.\nSubject rating of 60 vs 30-minute application.\nSubject rating of interest in using the patch.\nPain Quality Assessment Scale\nTenderness Rating Scale at 24-hours post injection", 
            "measure": "Average pain rating", 
            "safety_issue": "No", 
            "time_frame": "Average pain over 24 hours"
        }, 
        "source": "Brown, Theodore R., M.D., MPH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brown, Theodore R., M.D., MPH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}